GNPX

+ Watchlist + Portfolio

Genprex, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.99
52-Week Range: $3.83 – $1,210.00
Market Cap: $1.99M
P/E (TTM): 0.11
EPS (TTM): 34.43
Dividend Yield: —

Advanced Metrics

Price/Book: 0.14
PEG Ratio: —
Return on Equity: -203.86%
Return on Assets: -94.46%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 6.76
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-10.81M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-11.88M

GNPX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$11.51M	$17.62M	$10.54M	$9.43M
Selling, General & Admin	$12.30M	$13.43M	$10.63M	$6.09M
Operating Expenses	$23.83M	$31.06M	$21.17M	$15.52M
Operating Income	-$23.83M	-$31.06M	-$21.17M	-$15.52M
EBITDA	-$23.81M	-$31.04M	-$21.10M	-$15.49M
Pretax Income	-$23.74M	-$30.86M	-$21.11M	-$16.23M
Net Income	-$23.74M	-$30.86M	-$21.11M	-$16.23M
Diluted EPS	-21780.00	-24816.00	-5871.58	-382.80
Diluted Shares	1089	1243	3642	42396

GNPX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$20.95M	$6.74M	$1.60M	$7.83M
Receivables	$34.85K	$0.00	—	—
Current Assets	$21.47M	$7.53M	$2.08M	$8.36M
Total Assets	$25.09M	$10.67M	$4.12M	$10.16M
Current Liabilities	$2.81M	$3.25M	$2.50M	$2.17M
Total Liabilities	$2.81M	$3.25M	$2.50M	$2.20M
Retained Earnings	-$102.83M	-$133.69M	-$154.80M	-$171.03M
Shareholders' Equity	$22.27M	$7.42M	$1.62M	$7.96M
Working Capital	$18.66M	$4.28M	-$426.70K	$6.18M

GNPX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$17.62M	-$24.74M	-$17.92M	-$15.31M
Capital Expenditure	-$59.73K	-$71.38K	—	—
Free Cash Flow	-$17.68M	-$24.81M	-$17.92M	-$15.31M
Depreciation & Amortisation	$25.57K	$15.00K	$6.69K	$0.00
Stock-Based Compensation	$4.73M	$5.41M	$3.30M	$312.83K
Investing Cash Flow	-$59.73K	-$71.21K	$774.64K	$0.00
Financing Cash Flow	$6.43K	$10.59M	$12.01M	$21.54M
Net Change in Cash	-$17.67M	-$14.22M	-$5.14M	$6.23M

GNPX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.54M	$2.50M	$2.19M	$2.20M	$2.75M
Selling, General & Admin	$1.43M	$2.18M	$1.15M	$1.32M	$1.75M
Operating Expenses	$3.97M	$4.68M	$3.35M	$3.52M	$4.49M
Operating Income	-$3.97M	-$4.68M	-$3.35M	-$3.52M	-$4.49M
EBITDA	-$3.97M	-$4.68M	-$3.34M	-$3.51M	-$4.49M
Pretax Income	-$3.96M	-$4.67M	-$3.80M	-$3.79M	-$4.46M
Net Income	-$3.96M	-$4.67M	-$3.80M	-$3.79M	-$4.46M
Diluted EPS	-285.56	-187.00	-110.00	—	-14.08
Diluted Shares	13878	25085	34568	—	315999

GNPX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$3.47M	$1.35M	$1.10M	$7.83M	$18.05M
Current Assets	$4.16M	$2.06M	$1.72M	$8.36M	$18.80M
Total Assets	$6.01M	$3.83M	$3.56M	$10.16M	$20.31M
Current Liabilities	$2.14M	$2.44M	$2.55M	$2.17M	$3.35M
Total Liabilities	$2.14M	$2.44M	$2.79M	$2.20M	$3.38M
Retained Earnings	-$158.76M	-$163.44M	-$167.24M	-$171.03M	-$175.49M
Shareholders' Equity	$3.87M	$1.39M	$767.81K	$7.96M	$16.93M
Working Capital	$2.02M	-$380.14K	-$836.61K	$6.18M	$15.45M

GNPX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$4.16M	-$3.86M	-$3.19M	-$4.10M	-$3.14M
Free Cash Flow	-$4.16M	-$3.86M	-$3.19M	-$4.10M	-$3.14M
Depreciation & Amortisation	$0.00	$0.00	$0.00	$0.00	—
Stock-Based Compensation	$184.20K	$89.95K	$385.11K	-$346.42K	$73.43K
Investing Cash Flow	$0.00	$0.00	$0.00	$0.00	—
Financing Cash Flow	$6.03M	$1.74M	$2.94M	$10.83M	$13.36M
Net Change in Cash	$1.87M	-$2.12M	-$243.53K	$6.73M	$10.22M

Market Snapshot

About

Genprex, Inc. is a clinical-stage biopharmaceutical company developing targeted gene therapies for cancer and diabetes. The company's lead oncology candidate Reqorsa is a tumor suppressor gene therapy delivered through a proprietary nanoparticle delivery system for treatment of non-small cell lung cancer. Genprex is also developing Oncoprex immunogene therapy and diabetes treatment GPX-002 using its TUSC2 nanoparticle technology platform. The company's approach focuses on delivering therapeutic genes directly to diseased tissues while minimizing systemic exposure.